Founding Partner
i&i BioCheck size: €150K for company creation and roughly €500K-€2M for initial venture investments, as published by i&i Bio.
Karel Kubias, MBA invests or supports investment decisions through i&i Bio's published strategy: Invest in scientifically strong early-stage life-science companies, with primary focus on Central and Eastern Europe and selective opportunities across Europe.
Validated science, protectable intellectual property, credible translational plans and founders who can move discoveries toward clinical or commercial milestones.
No formal pass list is public. Projects without strong scientific validation, life-science relevance or a feasible development path appear less aligned.
Present the science, validation, IP, development and regulatory path, team, milestone budget and why i&i Bio's regional network matters.
No writing has been linked yet. Kit can search for posts, interviews, and fund essays worth reading before outreach.
No podcast appearances are linked yet. Ask Kit to check for interviews that reveal how this investor thinks.
Quote coverage is incomplete. Kit can look for direct comments on markets, founders, and investment criteria.
Karel Kubias, MBA is a current Founding Partner at i&i Bio. i&i Bio says he has more than 20 years of leadership experience in life sciences, pharmaceuticals and diagnostics, including executive roles at Merck.